Pseudomonas aeruginosa Type III Secretion System Virulotypes and Their Association with Clinical Features of Cystic Fibrosis Patients

References

• Athanazio RA, da Silva Filho LVRF, Vergara AA, et al. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumol. 2017;43(3):219–245.28746534
   PubMed Web of Science ®Google Scholar
• Marson FAL, Hortencio TDR, Aguiar KCA, et al. Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis. BMC Pulm Med. 2015;15(3). doi:10.1186/1471-2466-15-3.
   Web of Science ®Google Scholar
• Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531. doi:10.1016/S0140-6736(16)00576-627140670
   PubMed Web of Science ®Google Scholar
• Silva Filho LVRFD, Ferreira FDA, Reis FJC, et al. Infecção por Pseudomonas aeruginosa em pacientes com fibrose cística: evidências científicas sobre o impacto clínico, diagnóstico e tratamento. J Bras Pneumol. 2013;39(4):495–512. doi:10.1590/S1806-3713201300040001524068273
   PubMed Web of Science ®Google Scholar
• Crull MR, Ramos KJ, Caldwell E, Mayer-Hamblett N, Aitken ML, Goss CH. Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time. BMC Pulm Med. 2016;16(1):1–7. doi:10.1186/s12890-016-0333-y26728359
   PubMed Web of Science ®Google Scholar
• Parkins MD, Somayaji R, Waters VJ. Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis. Clin Microbiol Rev. 2018;31(4).
   PubMed Web of Science ®Google Scholar
• Pournajaf A, Razavi S, Irajian G, et al. Integron types, antimicrobial resistance genes, virulence gene profile, alginate production and biofilm formation in Iranian cystic fibrosis Pseudomonas aeruginosa isolates. Infez Med. 2018;26(3):226–236.30246765
   PubMedGoogle Scholar
• Vidya P, Smith L, Beaudoin T, et al. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2016;35(1):67–74. doi:10.1007/s10096-015-2509-426492874
   PubMed Web of Science ®Google Scholar
• Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35(S1):s1–s67. doi:10.1086/676882
   PubMed Web of Science ®Google Scholar
• Lee AC, Jones AL. Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis. Paediatr Respir Rev. 2018;27:18–20. doi:10.1016/j.prrv.2018.05.00929914746
   PubMed Web of Science ®Google Scholar
• Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013;67(3):159–173. doi:10.1111/2049-632X.1203323620179
   PubMed Web of Science ®Google Scholar
• Harmer CJ, Triccas JA, Hu H, et al. Pseudomonas aeruginosa strains from the chronically infected cystic fibrosis lung display increased invasiveness of A549 epithelial cells over time. Microb Pathog. 2012;53(1):37–43. doi:10.1016/j.micpath.2012.03.01122516803
   PubMed Web of Science ®Google Scholar
• Sawa T, Shimizu M, Moriyama K, Wiener-Kronish JP. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Crit Care. 2014;18(6):668. doi:10.1186/s13054-014-0668-925672496
   PubMed Web of Science ®Google Scholar
• Hu H, Harmer C, Anuj S, et al. Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening. Clin Microbiol Infect. 2013;19(3):266–272. doi:10.1111/j.1469-0691.2012.03770.x22329595
   PubMed Web of Science ®Google Scholar
• Bradbury RS, Roddam LF, Merritt A, Reid DW, Champion AC. Virulence gene distribution in clinical, nosocomial and environmental isolates of Pseudomonas aeruginosa. J Med Microbiol. 2010;59(8):881–890. doi:10.1099/jmm.0.018283-020430902
   PubMed Web of Science ®Google Scholar
• Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology. 2001;147(10):2659–2669. doi:10.1099/00221287-147-10-265911577145
   PubMed Web of Science ®Google Scholar
• Horna G, Amaro C, Palacios A, Guerra H, Ruiz J. High frequency of the exoU+/exoS+ genotype associated with multidrug-resistant “high-risk clones” of Pseudomonas aeruginosa clinical isolates from Peruvian hospitals. Sci Rep. 2019;9(1):1–13. doi:10.1038/s41598-019-47303-430626917
   PubMed Web of Science ®Google Scholar
• Morales-Espinosa R, Delgado G, Espinosa LF, et al. Fingerprint analysis and identification of strains ST309 as a potential high risk clone in a Pseudomonas aeruginosa population isolated from children with bacteremia in Mexico City. Front Microbiol. 2017;8:13. doi:10.3389/fmicb.2017.0031328167933
   PubMed Web of Science ®Google Scholar
• Finnan S, Morrissey JP, O’gara F, Boyd EF. Genome diversity of Pseudomonas aeruginosa isolates from cystic fibrosis patients and the hospital environment. J Clin Microbiol. 2004;42(12):5783–5792. doi:10.1128/JCM.42.12.5783-5792.200415583313
   PubMed Web of Science ®Google Scholar
• Peña C, Cabot G, Gómez-Zorrilla S, et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis. 2015;60(4):539–548. doi:10.1093/cid/ciu86625378459
   PubMed Web of Science ®Google Scholar
• El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med. 2012;40(4):1157–1163. doi:10.1097/CCM.0b013e318237790622080633
   PubMed Web of Science ®Google Scholar
• Jabalameli F, Mirsalehian A, Khoramian B, et al. Evaluation of biofilm production and characterization of genes encoding type III secretion system among Pseudomonas aeruginosa isolated from burn patients. Burns. 2012;38(8):1192–1197. doi:10.1016/j.burns.2012.07.03022995427
   PubMed Web of Science ®Google Scholar
• Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis: studies made over a five-to fourteen-year period. AMA J Dis Child. 1958;96(1):6–15. doi:10.1001/archpedi.1958.0206006000800213544726
   PubMedGoogle Scholar
• Pereira C. Sociedade Brasileira de Pneumologia e Tisiologia, Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes para testes de função pulmonar. J Pneumol. 2002;28(Suppl 3):S1–238.
   Google Scholar
• Zhu H, Conibear TC, Bandara R, Aliwarga Y, Stapleton F, Willcox MD. Type III secretion system–associated toxins, proteases, serotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis. Curr Eye Res. 2006;31(4):297–306. doi:10.1080/0271368050053674616603462
   PubMed Web of Science ®Google Scholar
• Ayres M, Ayres Júnior M, Ayres DL, Santos AS. BioEstat 5.0. Aplicações Estatísticas Nas Áreas Das Ciências Bio-Médicas. Belém (PA): Instituto de Desenvolvimento Sustentável Mamirauá; 2008.
   Google Scholar
• Juarez-Colunga E, Rosenfeld M, Zemanick ET, Wagner B. Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. J Cyst Fibros. 2020;19(1):114–118. doi:10.1016/j.jcf.2018.12.00530642785
   PubMed Web of Science ®Google Scholar
• Luo RG, Miao XY, Luo LL, Mao B, Yu FY, Xu JF. Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non–cystic fibrosis bronchiectasis patients. Clin Microbiol Infect. 2019;25(5):601–606. doi:10.1016/j.cmi.2018.07.00830036669
   PubMed Web of Science ®Google Scholar
• Lanotte P, Mereghetti L, Lejeune B, Massicot P, Quentin R. Pseudomonas aeruginosa and cystic fibrosis: correlation between exoenzyme production and patient’s clinical state. Pediatr Pulmonol. 2003;36(5):405–412. doi:10.1002/ppul.1038014520723
   PubMed Web of Science ®Google Scholar
• Mitov I, Strateva T, Markova B. Prevalence of virulence genes among bulgarian nosocomial and cystic fibrosis isolates of Pseudomonas aeruginosa. Braz J Microbiol. 2010;41(3):588–595. doi:10.1590/S1517-8382201000030000824031533
   PubMed Web of Science ®Google Scholar
• Khodayary R, Nikokar I, Mobayen MR, et al. High incidence of type III secretion system associated virulence factors (exoenzymes) in Pseudomonas aeruginosa isolated from Iranian burn patients. BMC Res Notes. 2019;12(1):1–6. doi:10.1186/s13104-019-4071-030602384
   PubMed Web of Science ®Google Scholar
• Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol. 2009;12(1):61–66. doi:10.1016/j.mib.2008.12.00719168385
   PubMed Web of Science ®Google Scholar
• Lanotte P, Watt S, Mereghetti L, et al. Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. J Med Microbiol. 2004;53(1):73–81. doi:10.1099/jmm.0.05324-014663109
   PubMed Web of Science ®Google Scholar
• Römling U, Fiedler B, Boßhammer J, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis. 1994;170(6):1616–1621. doi:10.1093/infdis/170.6.16167996008
   PubMed Web of Science ®Google Scholar
• Parkins MD, Glezerson BA, Sibley CD, et al. Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol. 2014;52(4):1127–1135. doi:10.1128/JCM.03218-1324452167
   PubMed Web of Science ®Google Scholar
• Logan C, Habington A, Lennon G, et al. Genetic relatedness of Pseudomonas aeruginosa isolates among a paediatric cystic fibrosis patient cohort in Ireland. J Med Microbiol. 2012;61(1):64–70. doi:10.1099/jmm.0.035642-021921114
   PubMed Web of Science ®Google Scholar
• Hauser AR, Cobb E, Bodí M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med. 2002;30(3):521–528. doi:10.1097/00003246-200203000-0000511990909
   PubMed Web of Science ®Google Scholar